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Abstract
Purpose—Patients diagnosed with invasive breast cancer (BC) or ductal carcinoma in situ are 
increasingly choosing to undergo contralateral prophylactic mastectomy (CPM) to reduce their 
risk of contralateral breast cancer (CBC). This is a particularly disturbing trend as a large 
proportion of these CPMs are believed to be medically unnecessary. Many BC patients tend to 
substantially overestimate their CBC risk. Thus, there is a pressing need to educate patients 
effectively on their CBC risk. We develop a CBC risk prediction model to aid physicians in this 
task.
Methods—We used data from two sources: Breast Cancer Surveillance Consortium and 
Surveillance, Epidemiology, and End Results to build the model. The model building steps are 
similar to those used in developing the Breast Cancer Risk Assessment Tool (popularly known as 
Gail model) for counseling women on their BC risk. Our model, named Contralateral Breast 
Cancer Risk (CBCRisk) is exclusively designed for counseling women diagnosed with unilateral 
BC on the risk of developing CBC.
Results—We identified eight factors to be significantly associated with CBC–age at first BC 
diagnosis, anti-estrogen therapy, family history of BC, high risk pre-neoplasia, estrogen receptor 
status, breast density, type of first BC, and age at first birth. Combining the relative risk estimates 
with the relevant hazard rates, CBCRisk projects absolute risk of developing CBC over a given 
period.
Conclusions—By providing individualized CBC risk, CBCRisk may help in counseling of BC 
patients. In turn, this may potentially help alleviate the rate of medically unnecessary CPMs.
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Introduction
The last two decades have seen a sharp increase in the rate of contralateral prophylactic 
mastectomy (CPM) in patients diagnosed with ductal carcinoma in situ (DCIS) or invasive 
breast cancer (BC) [1–6]. Paradoxically, the same periods over which the CPM rate has 
increased are also the periods over which the risk of contralateral breast cancer (CBC) has 
decreased [7]. The fall in CBC risk is most likely due to increasing use of effective adjuvant 
therapies such as tamoxifen and aromatase inhibitors for treating primary BC [8–10], which 
also have a protective effect on the contralateral breast. Historically, the CBC rate has been 
quoted to be 0.5% to 0.75% per year but these estimates are considered outdated with some 
recent population-based studies estimating it to be 0.1% to 0.3% per year for most women 
[11–17]. In fact, for the majority of patients affected with first primary BC, their CBC risk is 
much smaller than the risk of recurrence from their index cancer [3].
Several risk factors for CBC have been identified in the literature such as BRCA1/2 
mutations, young age at diagnosis of the first primary, family history of BC, lobular 
histology, negative estrogen receptor/progesterone receptor (ER/PR) status, positive lymph 
node status, and larger tumor size [13,15,17–26]. On the other hand, protective factors for 
CBC include premenopausal oophorectomy, adjuvant hormonal therapy, chemotherapy, and 
CPM [12,20,25,27,28].
For typical BC patients though, the individual CBC risk is relatively low because the factors 
associated with increased risk are found only in small proportions of BC patients. For 
example, only a small percentage of BC patients are BRCA1/2 mutation carriers, and 
women without family history of BC are more prevalent than those with family history 
[15,20]. Thus, evidently the actual CBC risk does not drive the decision of whether to 
undergo CPM. In fact, the CPM rate has primarily increased in the group of women who are 
at low risk of CBC [17]. This apparently paradoxical relationship has led to a flurry of 
investigations into factors driving the decision of CPM including the perceptions about CBC 
risk [14,16,17]. Not surprisingly, it has been found that patients tend to perceive their CBC 
risk to be much higher than the actual risk, sometimes even by a factor of 5 to 10 [17,29,30]. 
To some women, CPM may seem as an opportunity to escape from the anxiety and stress 
associated with surveillance if they decide to keep their healthy breast [16,17]. Recent 
advances in reconstruction techniques and considerations for shape and symmetry in both 
breasts also play a role in this decision [16,17]. Nonetheless, these psychological and 
physical benefits must be weighed against the loss of a healthy breast in the light of actual 
risk of CBC and the risks, negative effects, and irreversible nature of CPM [3,16,17,28,31–
39]. Another factor to consider is that there is little to no convincing evidence that CPM 
prolongs either overall or BC-specific survival or reduces BC mortality in women with 
sporadic BC [17,28,31–34].
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Notwithstanding the above arguments, it is quite understandable for women traumatized by 
the diagnosis of unilateral BC to instinctively lean towards CPM if only as an anxiety-
relieving tool. This is especially true if they perceive their CBC risk to be high. Thus, it is 
critical for physicians to review with their patients the various aspects of this complex 
decision. To aid physicians in this task, a readily available tool that can provide objective, 
quantitative, and personalized estimate of CBC risk is needed. An educated patient can be 
expected to make an informed decision, which may or may not be to undergo CPM.
In this study, we developed a statistical model for estimating individualized risk of CBC. In 
particular, we developed an absolute risk prediction model along the lines of the Breast 
Cancer Risk Assessment Tool, popularly known as Gail model [40], which is widely used 
for predicting risk of first primary BC in healthy women. Our model, named Contralateral 
Breast Cancer Risk (CBCRisk), is applicable for women diagnosed with first primary of 
unilateral invasive BC and/or DCIS.
Data Sources and Methods
Data Sources
We used prospectively collected data from two sources: Breast Cancer Surveillance 
Consortium (BCSC) and Surveillance, Epidemiology, and End Results (SEER) [41,42]. 
BCSC data were used to build the relative risk model and to compute the attributable risk 
while SEER data were used for calculating age-specific composite CBC hazard rates and 
mortal hazard rates from non-CBC causes.
BCSC data were collected on women undergoing mammography at seven registries across 
the USA [43]. We started with a cohort of women who had their first breast cancer 
diagnosed between ages 18–88 years and years 1995–2009. For each woman, only those BC 
diagnoses were considered that were of type invasive and/or DCIS. Women satisfying any of 
the following criteria were excluded–(a) their first BC diagnosis was made solely by 
mammography (i.e., no histological confirmation), (b) they underwent CPM, (c) their race 
was unknown or unclear, (d) they had undergone radiation therapy before the first BC 
diagnosis, (e) their first BC was bilateral or had unknown laterality, and (f) their second 
diagnosis (or a subsequent one if all diagnoses before it are of the same laterality as the first 
one) had unknown laterality.
After applying the above inclusion and exclusion criteria, there were 77,746 women in the 
BCSC cohort. We define a woman to be a case if her CBC diagnosis was made at least 6 
months after the first BC diagnosis. Among 77,746 women, 1,921 were CBC cases and the 
rest 75,825 were eligible to be controls. The follow-up for each woman in this cohort starts 
at the time of her first BC diagnosis. For a case, the follow-up ends at the time of her CBC 
diagnosis, whereas for a control, the follow-up ends at death or censoring in 2009, the BCSC 
cut-off year. We matched the eligible controls to cases to get a case-control dataset for 
building the relative risk model. Specifically, for each case, we randomly selected 3 women 
from among the eligible controls who matched the case on race (White-non Hispanic, Black-
non Hispanic, Hispanic, Asian, or other) and year of first BC diagnosis, and whose length of 
follow-up was at least as long as that of the case. As current age and age at first BC 
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diagnosis are important risk factors, we did not use them for matching criteria to allow the 
possibility of including them in the model. This resulted in a total of 5,763 controls being 
selected for the case-control dataset.
SEER data include 18 registries from across the USA. We used data from years 1998–2013 
and applied the same inclusion and exclusion criteria as for BCSC data except that prior 
radiation therapy information was not available in the SEER database. Finally, our SEER 
cohort included 824,768 women with 19,835 cases and 804,933 eligible controls.
The registries and the Statistical Coordinating Center (SCC) of BCSC have institutional 
review board approval for either active or passive consenting processes or a waiver of 
consent to enroll participants, link data, and perform analytic studies. Their procedures are 
Health Insurance Portability and Accountability Act (HIPAA) compliant. Besides, they have 
received a Federal Certificate of Confidentiality, and have instituted controls for protection 
for the identities of women, physicians, and facilities who are subjects of this research.
Model Building Strategy
We built CBCRisk following the steps similar to those used in developing the Gail model 
[40] Specifically, there are four steps in the model building procedure–(1) identifying the 
risk factors for CBC and building the relative risk model, (2) estimating the baseline age-
specific CBC hazard rates by combining the age-specific composite CBC hazard rates and 
attributable risk fractions, (3) computing mortal hazard rates from non-CBC causes, and (4) 
combining results from steps 1, 2, and 3 to get the projection of absolute risk of CBC.
In step 1, we investigated a large number of potential predictors. This includes current age 
(defined as the age at last follow-up), age at first BC diagnosis, menopausal status, tumor 
size, status of ER, PR human epidermal growth factor receptor 2 (HER2), number of 
positive lymph nodes, chemotherapy, biopsy status, first degree family history of breast 
cancer, personal or family history of ovarian cancer, high risk pre-neoplasia status, breast 
density (obtained using the BI-RADS system), age at first birth, hormone replacement 
therapy, anti-estrogen therapy, stage of first BC, tumor node status, body mass index, and 
type of first BC (pure DCIS, pure invasive, or a mix of the two). Each of these variables was 
ascertained from the records available at the time of the first BC diagnosis. The variable high 
risk pre-neoplasia status was defined as ‘yes’ if a patient had lobular carcinoma in situ 
(LCIS) in their first BC and/or had a history of atypical hyperplasia in any breast prior to 
their first BC, otherwise, the category was set to ‘no/unknown.’ The ‘no’ and ‘unknown’ 
categories were combined because the ‘no’ response provided by the pathology report may 
also include incomplete information about pre-neoplasia. To accommodate missing 
information, we allowed “unknown” as one of the categories in most variables. We also 
explored interactions between several risk factors, however, some interactions could not be 
considered because of the limited number of subjects available at the combinations of the 
risk factors involved. The final multivariate model was obtained by applying the standard 
variable selection methods [44]. More details about each of the four model building steps are 
provided in Supplementary Materials.
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We used statistical software R [45] for all computations. We have developed an R package 
implementing CBCRisk and a freely available app, which are available at http://
www.utdallas.edu/~swati.biswas/ and http://www.utdallas.edu/~pankaj/. The R package has 
also been integrated into CancerGene, a widely used cancer risk prediction tool, which will 
be available soon from the HughesRiskApps site (http://www.hughesriskapps.net/
index.php).
Results
The final multivariate relative risk model includes eight risk factors–age at first BC 
diagnosis, hormone therapy, first degree family history of breast cancer, high risk pre-
neoplasia status, ER status, breast density, first BC type, and age at first birth. The estimates 
of relative risks and their 95% confidence intervals (CI) along with the counts of cases and 
controls in each category of a risk factor are summarized in Table 1. Note that all variables 
allow an unknown (missing) category except the age at first diagnosis and first BC type. We 
find that younger age at the first diagnosis, family history of BC, and negative ER status are 
associated with higher risk of CBC while anti-estrogen therapy reduces the risk. These 
findings are consistent with the literature [12,20,25,27,28]. A history of high risk pre-
neoplasia corresponds to an increased risk even though only a few women in BCSC data 
were known to have such a history. Interestingly, breast density has an increasing dose effect 
on CBC risk with increased density associated with increased risk. Similar increasing dose 
effect is observed for presence of DCIS in the first BC type–invasive BC with associated 
DCIS (mixed invasive-DCIS) has increased CBC risk compared to pure invasive and the risk 
goes further up for pure DCIS. Older age at first birth corresponds to a higher risk; in 
particular, the risk goes up substantially for 40+ group. However, we note that the sample 
sizes are small for this category (as well as for some categories of other variables) leading to 
wider CIs.
In defining the categories for the age at first birth variable, we combined nulliparous and <30 
age categories as their estimated relative risks were similar. For age at first BC diagnosis, we 
had also explored finer categories but did not find any improvement in the results. None of 
the interaction terms that we were able to consider were found to be significant. The final 
relative risk model does not have current age of a woman as a risk factor as it was highly 
correlated with the age at first BC diagnosis. Thus, both the factors could not be in the 
model together. We excluded current age and retained age at first BC diagnosis. As current 
age is not in the relative risk model, the relative risks are constant over time. Nonetheless, 
current age does play a role in the final absolute risk model through age-specific hazard 
rates.
Figure 1 shows the age-specific composite CBC incidence rates per 1,000 person-years. It 
ranges between 2.6 and 4.4, with lowest value over the interval [18, 30) and highest over the 
interval [75, 80). It exhibits little fluctuation around 3.5 over the intervals [30, 65) and [85, 
90), and around 4.1 over the interval [65, 85). Thus, on the whole, we may conclude that the 
CBC incidence rate increases from 2.6 over the interval [18, 30) to about 3.5 over the 
interval [30, 65) and further to about 4.1 over the interval [65, 85), and declines thereafter to 
3.5.
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Figure 2 shows the age-specific non-CBC mortal hazard rates per 1,000 person-years. 
Starting at 35, the rate decreases steadily to about 15 around age 40, essentially stays there 
till around age 65, and increases steadily thereafter to 83 by age 90.
In Table 2, we present 5-year and 15-year projected absolute risks of CBC for a wide range 
of combinations of risk factors and current age. We can see clearly that the risk varies 
substantially depending on the specific combination of risk factors a woman has. The second 
last row represents a typical woman in BCSC data in terms of each risk factor, where by 
“typical”, we mean a woman with the most frequently occurring value for each factor. As the 
most common category for many factors is “unknown”, we also show in the last row a 
typical woman after excluding “unknown” category. We see that 5-year and 15-year CBC 
risks are roughly 1.5% and 4.5%, respectively, for both women. This illustrates that the CBC 
risk for a typical BC patient is not high, contrary to the perceived notion.
Discussion
For a patient diagnosed with unilateral BC, the risk of CBC is a fundamental concern. Yet 
there is no prediction model available for assessing the risk in a personalized and 
quantitative manner for the general population. The need for such a model is especially dire 
in the light of the paradoxical situation of increasing rates of CPM in the times of falling 
CBC rates and mounting evidence of little or no survival benefits of CPM. To fulfill this 
need, we have developed a model called CBCRisk. This model utilizes several relevant risk 
factors that we found to be significant. Our findings are consistent with the literature in that 
a family history of breast cancer, a younger age of first BC diagnosis, and an ER negative 
status are associated with increased CBC risk while anti-estrogen therapy has a protective 
effect [12,20,25,27,28,46]. The effect of breast density has attracted substantial research 
interest in the recent years. Our study adds to the literature in this regard by finding that 
breast density has an increasing dose effect on CBC risk. DCIS has also drawn attention 
lately and our result indicates that presence of DCIS in the first BC, either in a mixed or pure 
form, also increases the chance of CBC.
We found that the CBC risk can vary greatly depending on the risk factors and thus using a 
one-size-fits-all estimate such as the commonly cited 0.5% CBC risk per year can be 
misleading for many patients. For typical BC patients though, the CBC risk does not appear 
to be high. Availability of a quantitative and individualized risk estimate as provided by 
CBCRisk can aid physicians in educating their patients effectively. This, in turn, will 
empower patients to make an informed decision, which may or may not be to undergo CPM.
We have also used the BCSC data for calculating the age-specific hazard rates (in step 2 of 
model building). These rates were similar to those we presented in Figures 1 and 2 using 
SEER data except at the two extreme ends of age-intervals for which the BCSC data lack 
sufficient sample sizes and hence are subject to greater variability. As SEER rates are based 
on a much larger dataset, we decided to use those rates in our risk calculations. However, 
SEER lacks information on several risk factors for CBC, which precluded its use for 
building the relative risk component of the model.
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Our study has several limitations. One is missing/unknown information in several variables. 
As a certain amount of missing information is inevitable in most clinical situations, we 
allowed such a category for most of the variables so that our model can still be used. 
Nonetheless, the relative risks associated with the “unknown” categories must be interpreted 
with caution keeping in mind that an “unknown” category is actually a mixture of the other 
categories and its definition/composition for a variable may not be stable across populations. 
Further, due to small sample sizes for some specific combinations of factors, we could not 
study all two-way interactions. Also, a few variables such as oophorectomy and family 
history of breast and ovarian cancers are self-reported.
Another limitation is that the BCSC data do not contain information on the type of anti-
estrogen therapy. Thus, CBCRisk treats tamoxifen and aromatase inhibitors in the same way, 
even though the latter are known to be more protective for CBC [8,10]. In future, we plan to 
update our model based on other data sources that have information on the type of anti-
estrogen therapy.
The BCSC data lacks information on some risk factors for CBC such as BRCA1/2 status and 
family history of BC beyond first-degree relatives. Even among the first-degree relatives, the 
BCSC data do not specify which specific relative has breast cancer. Thus, CBCRisk uses 
limited family history information and is mainly intended for sporadic BC patients. For 
patients with a strong family history of breast or ovarian cancer and/or who are carrying 
BRCA1/2 mutations, the Mendelian genetic risk prediction model BRCAPRO [47] is 
preferable as it uses extensive family history information including ovarian cancer. However, 
BRCAPRO does not utilize several covariates that are used in CBCRisk. Thus, it will be 
worthwhile to pool the strengths of the two models in a joint model that uses covariates from 
CBCRisk as well as somewhat more detailed family history information. For this, it may be 
preferable to use simplified versions of BRCAPRO [48] to limit the burden of family history 
collection for the general population of BC patients. Finally, it will be of interest to validate 
CBCRisk with independent data. Another future work could be to evaluate the effectiveness 
of CBCRisk in educating patients.
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Refer to Web version on PubMed Central for supplementary material.
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Age-specific composite incidence rates of CBC estimated using SEER data. Age on the 
horizontal axis can be interpreted as age at counseling.
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Age-specific mortal hazard rates from non-CBC causes estimated using SEER data. Age on 
the horizontal axis can be interpreted as age at counseling.
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